Venetoclax, for example, disrupts BCL2–BCL2 interactions to induce apoptosis in malignant cells [59], whereas Motixafortide antagonizes the CXCL12–CXCR4 axis to mobilize hematopoietic stem cells for the treatment of multiple myeloma [60]. The gene discussed is BCL2; the disease is AL amyloidosis.